Asset profile
ZT002
Peptide
Evidence outlook · lead readout
NCT07020884 · Overweight or Obesity
The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.
NCT07020884: The study was randomized and double-blind, included a placebo comparator, and enrolled 303 participants. However, the primary endpoint—percentage change in body weight after 24 weeks—has no posted results, so whether the treatment was effective is unknown.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.